EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Evolving Role of Obinutuzumab in the Treatment of Splenic Marginal Zone Lymphoma

Maria K. Angelopoulou, Eliana Α. Konstantinou, Ioannis Vasilopoulos, John V. Asimakopoulos, Stavrianna Diavati, Marina P. Siakantaris, Panayiotis Panayiotidis, Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis

Case Reports in Hematology · 2026-01 · 2026 (1)

DOI: 10.1155/crh/9995534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Hematology, online erschienen am 16.03.2026. Verfasst von Maria K. Angelopoulou und 8 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of obinutuzumab is established in chronic lymphocytic leukemia and follicular lymphoma. Its role in less frequent B‐cell lymphomas is not yet clear. Rituximab monotherapy is an established first‐line treatment in splenic marginal zone lymphoma (SMZL), leading to excellent and long‐lasting remissions, with less than 10% of patients experiencing suboptimal responses. We here report the first two cases of rituximab‐refractory SMZL patients, responding to obinutuzumab monotherapy. They had previously received six weekly rituximab infusions at first line and experienced stable disease with persistent splenomegaly and extensive bone marrow infiltration. Obinutuzumab was administered for six weekly infusions as second‐line treatment. Both of them achieved durable complete responses with full restoration of cytopenias and complete resolution of splenomegaly and bone marrow infiltration. At the present follow‐up, they are still without any evidence of disease at 37 and 20 months posttreatment, respectively. Thus, obinutuzumab monotherapy represents a valuable therapeutic option in SMZL, especially for rituximab‐refractory patients, offering a time‐limited therapy compared to ibrutinib, sparing chemotherapy‐associated myelotoxicity, and splenectomy morbidity.

Zitieren

APA

Angelopoulou, M. K., Konstantinou, E. Α., Vasilopoulos, I., Asimakopoulos, J. V., Diavati, S., Siakantaris, M. P., Panayiotidis, P., Vassilakopoulos, T. P., & Pangalis, G. A. (2026). The Evolving Role of Obinutuzumab in the Treatment of Splenic Marginal Zone Lymphoma. Case Reports in Hematology, 2026(1). https://doi.org/10.1155/crh/9995534

Vancouver

Angelopoulou MK, Konstantinou EΑ, Vasilopoulos I, Asimakopoulos JV, Diavati S, Siakantaris MP, et al. The Evolving Role of Obinutuzumab in the Treatment of Splenic Marginal Zone Lymphoma. Case Reports in Hematology. 2026;2026(1). doi:10.1155/crh/9995534

BibTeX
@article{Angelopoulou2026,
  author = {Angelopoulou, Maria K. and Konstantinou, Eliana Α. and Vasilopoulos, Ioannis and Asimakopoulos, John V. and Diavati, Stavrianna and Siakantaris, Marina P. and Panayiotidis, Panayiotis and Vassilakopoulos, Theodoros P. and Pangalis, Gerassimos A.},
  title = {The Evolving Role of Obinutuzumab in the Treatment of Splenic Marginal Zone Lymphoma},
  journal = {Case Reports in Hematology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crh/9995534}
}
Kostenlos starten →